Homepage
Author:
SOLIGENIX, INC.
Posted Date:
May 8, 2026
Soligenix Announces Recent Updates and First Quarter 2026 Financial Results
SOLIGENIX, INC.
May 8, 2026
Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma
SOLIGENIX, INC.
May 3, 2026
Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy
SOLIGENIX, INC.
April 30, 2026
Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results
SOLIGENIX, INC.
April 30, 2026
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet’s Disease
SOLIGENIX, INC.
March 26, 2026
1
2
3
Next
